Intrinsiqq
Intellia Therapeutics Inc. logo

Intellia Therapeutics Inc. Dividend Analysis

NTLA

⊜ Compare
Dividend0
No active dividend

This company has no dividend history.

Based on TTM and annual data · Not a buy/sell signal

This company does not pay dividends

No dividend history found in SEC filings.

Does Intellia Therapeutics (NTLA) pay a dividend?

Intellia Therapeutics (NTLA) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.

Frequently asked

Does Intellia Therapeutics (NTLA) pay a dividend?+

No. Intellia Therapeutics (NTLA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

How does Intellia Therapeutics return cash to shareholders?+

It largely does not. Intellia Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Could Intellia Therapeutics afford to pay a dividend?+

Not currently. Intellia Therapeutics's free cash flow is negative at -$349 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.

Which healthcare companies do pay dividends?+

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Intellia Therapeutics.

SourceDividend analysis computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.

Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with NTLA

CompareIntrinsic value
TKNOAlpha Teknova, Inc.
$7.37+0.41%15
ICCCImmuCell Corporation
$10.37+1.17%65
NNNNAnbio Biotechnology Ltd
$3.68+2.65%51
CSBRChampions Oncology, Inc.
$4.83+0.00%26
PRTAProthena Corporation plc
$8.39+2.19%25
SPROSpero Therapeutics Inc.
$1.07+2.88%63
BCYCBicycle Therapeutics PLC
$3.72+1.36%40
TNGXTango Therapeutics Inc.
$23.18+0.04%40

Held by ETFs

NTLA is in 46 US ETFs. The largest of them, with NTLA's weight in each:

Spot a number that looks wrong? Check it in NTLA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NTLA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.